240 related articles for article (PubMed ID: 15584861)
1. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
Steelman LS; Bertrand FE; McCubrey JA
Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
[TBL] [Abstract][Full Text] [Related]
2. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
3. PTEN: life as a tumor suppressor.
Simpson L; Parsons R
Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
[TBL] [Abstract][Full Text] [Related]
4. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.
Besson A; Robbins SM; Yong VW
Eur J Biochem; 1999 Aug; 263(3):605-11. PubMed ID: 10469123
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
[TBL] [Abstract][Full Text] [Related]
6. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
[TBL] [Abstract][Full Text] [Related]
7. Signalling through phosphoinositide 3-kinases: the lipids take centre stage.
Leevers SJ; Vanhaesebroeck B; Waterfield MD
Curr Opin Cell Biol; 1999 Apr; 11(2):219-25. PubMed ID: 10209156
[TBL] [Abstract][Full Text] [Related]
8. The INPP4B paradox: Like PTEN, but different.
Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
[TBL] [Abstract][Full Text] [Related]
9. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
10. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
[TBL] [Abstract][Full Text] [Related]
11. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles.
Déléris P; Bacqueville D; Gayral S; Carrez L; Salles JP; Perret B; Breton-Douillon M
J Biol Chem; 2003 Oct; 278(40):38884-91. PubMed ID: 12847108
[TBL] [Abstract][Full Text] [Related]
12. Biological role of phosphatase PTEN in cancer and tissue injury healing.
Tsugawa K; Jones MK; Sugimachi K; Sarfeh IJ; Tarnawski AS
Front Biosci; 2002 May; 7():e245-51. PubMed ID: 11991859
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin's resurrection: a new way to target the cancer cell cycle.
Garber K
J Natl Cancer Inst; 2001 Oct; 93(20):1517-9. PubMed ID: 11604470
[No Abstract] [Full Text] [Related]
14. Regulation of the PTEN phosphatase.
Gericke A; Munson M; Ross AH
Gene; 2006 Jun; 374():1-9. PubMed ID: 16675164
[TBL] [Abstract][Full Text] [Related]
15. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
Koul D; Jasser SA; Lu Y; Davies MA; Shen R; Shi Y; Mills GB; Yung WK
Oncogene; 2002 Apr; 21(15):2357-64. PubMed ID: 11948419
[TBL] [Abstract][Full Text] [Related]
16. The tumour suppressor PTEN: involvement of a tumour suppressor candidate protein in PTEN turnover.
Maehama T; Okahara F; Kanaho Y
Biochem Soc Trans; 2004 Apr; 32(Pt 2):343-7. PubMed ID: 15046605
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
Maehama T; Dixon JE
J Biol Chem; 1998 May; 273(22):13375-8. PubMed ID: 9593664
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
19. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.
Freeburn RW; Wright KL; Burgess SJ; Astoul E; Cantrell DA; Ward SG
J Immunol; 2002 Nov; 169(10):5441-50. PubMed ID: 12421919
[TBL] [Abstract][Full Text] [Related]
20. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
